Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2022 | $34.00 → $36.00 | Buy | HC Wainwright & Co. |
| 11/2/2021 | $32.00 → $34.00 | Buy | HC Wainwright & Co. |
| 10/7/2021 | $32.00 | Buy | HC Wainwright & Co. |
8-K - Lantern Pharma Inc. (0001763950) (Filer)
424B5 - Lantern Pharma Inc. (0001763950) (Filer)
144 - Lantern Pharma Inc. (0001763950) (Subject)
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $36.00 from $34.00 previously
HC Wainwright & Co. reiterated coverage of Lantern Pharma with a rating of Buy and set a new price target of $34.00 from $32.00 previously
HC Wainwright & Co. initiated coverage of Lantern Pharma with a rating of Buy and set a new price target of $32.00
AUSTIN, Texas, July 16, 2025 (GLOBE NEWSWIRE) -- via IBN -- Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform to transform the cost, pace and precision of oncology drug development, has selected IBN, a multifaceted financial news and publishing company serving private and public entities, to spearhead its corporate communications efforts. Lantern Pharma is redefining oncology drug development through its AI-powered RADR® platform, which integrates over 200 billion oncology-specific data points to guide drug discovery and clinical trial design. The company is advancing a precision oncolo
The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR ®, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030 Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast canc
Lantern Pharma Inc. (NASDAQ:LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announces remarkable clinical observations for a patient in Lantern's Phase 2 HARMONIC™ clinical trial. A 70-year-old never-smoker with advanced non-small cell lung cancer (NSCLC) has achieved a durable complete response in their target cancer lesions following treatment with LP-300 in combination with standard-of-care chemotherapy. Importantly, the patient continues to show sustained survival benefits after nearly two years. The patient, who had previously failed three lines of prior therapy including Keytruda (pembrolizumab) with
DALLAS, Sept. 2, 2021 /PRNewswire/ -- Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced the addition of two senior industry executives to support the Company's clinical and manufacturing initiatives. Dr. Harry Kochat has been appointed Senior Director of Chemistry, Manufacturing and Controls (CMC) and Manufacturing Quality Affairs, where his responsibilities will include oversight of drug candidate manufacturing and quality control. Darlene Bunpian, MPH has been appointed Clinical Trial Project Manag
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13G/A - Lantern Pharma Inc. (0001763950) (Subject)
SC 13D/A - Lantern Pharma Inc. (0001763950) (Subject)
Completion of LP-184 Phase 1a clinical trial enrollment with 62-65 patients across a range of solid tumors expected by end of June 2025. Additional patient data readout from the HARMONIC™ Trial evaluating LP-300 in never-smokers with non-small cell lung cancer (NSCLC) anticipated in Q3 2025, including initial readout for patients from the Asian expansion cohort. Strengthened AI intellectual property portfolio with PCT publication of proprietary blood-brain barrier penetration prediction patent application; favorable PCT search report indicated no significant prior art. Expanded RADR® platform with innovative AI-powered module to improve the precision, cost and timeline of antibody
Webcast to be held Thursday, May 15th, 9:00 a.m. ET, register for the webcast here, or at the link provided below. Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its first quarter 2025 operating and financial results webcast on Thursday, May 15, 9:00 a.m. Eastern Time / 6:00 a.m. Pacific Time. Management intends to discuss the operating and financial results for the first quarter ended March 31, 2025 and provide guidance on upcoming milestones, clinical tria
HARMONIC™ trial lead-in cohort delivered impressive 86% clinical benefit rate and 43% objective response rate in never-smoker NSCLC patients, with current expansion cohort reinforcing these positive trends as enrollment accelerates in Japan and Taiwan, where 33-40% of NSCLC cases occur in never-smokers, positioning Lantern for multiple clinical readouts in 2025. LP-184 received two U.S. FDA Fast Track Designations in 2024 for Glioblastoma and Triple Negative Breast Cancer, plus three additional Rare Pediatric Disease Designations, strengthening future market potential across multiple high-need indications with multi billion U.S. dollar market potential. Successfully dosed multiple pati
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)
4 - Lantern Pharma Inc. (0001763950) (Issuer)